When you're considering hyperbaric oxygen therapy, clinical statistics only get you so far. You want to know what real people experienced and whether it was worth the cost.
This article walks through what the published trials actually show, organized by condition, with honest expectations for what HBOT can and can't deliver in 2026.
If you're new to HBOT, start with our beginner's guide first, then come back here.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Individual results vary based on condition severity, treatment protocol, and overall health. HBOT should be pursued only under qualified physician supervision at a UHMS-accredited facility. Always consult your physician before starting HBOT.
Wound Healing: Where HBOT Has the Strongest Evidence
Wound healing is where HBOT has its deepest evidence base. The FDA has cleared HBOT for several wound-related conditions and the clinical literature consistently backs that clearance.
Diabetic Foot Ulcers
Chronic non-healing wounds, particularly diabetic foot ulcers, represent the most well-studied HBOT application.
The Cochrane Review by Liu et al. (2024) of HBOT for chronic wounds found a significant improvement in major amputation rates and ulcer healing for diabetic foot ulcers receiving HBOT versus standard care alone.
A randomized trial published in Löndahl et al., Diabetes Care 2010 found complete healing in 52% of Wagner Grade 2-4 ulcers receiving HBOT versus 29% in the control group at 1-year follow-up.
Radiation Tissue Injury
A 62-year-old woman treated at a major academic wound center for radiation-induced soft tissue necrosis following breast cancer is a typical case profile. After 40 sessions at 2.0 ATA, transcutaneous oxygen pressure (TcPO2) improved enough to support successful reconstructive surgery.
Soft tissue radionecrosis and osteoradionecrosis are both on the UHMS 15th Edition Indications list (2025). The evidence base includes the HORTIS trial program (Bennett et al., Cochrane 2016) on radiation injury.
The Mechanism
What makes wound healing outcomes compelling is the biology.
At 2.0 ATA on 100% oxygen, dissolved plasma oxygen rises roughly 15-fold over breathing room air at sea level per Henry's Law calculations in StatPearls HBOT Physiology (2024).
That hyper-oxygenated plasma reaches ischemic tissue red blood cells can't penetrate due to damaged microvasculature. Oxygen stimulates angiogenesis, fibroblast proliferation, and collagen synthesis. It's not magic. It's physiology, well documented and reproducible.
What Outcomes Look Like in Hospital Settings
Hospital wound centers integrate HBOT into comprehensive wound care programs — advanced dressings, negative pressure therapy, vascular interventions. The multi-modal approach tends to produce the best outcomes.
HBOT alone helps. HBOT as part of a coordinated wound plan helps more.
If you're dealing with a chronic wound that hasn't responded to conventional treatment, the evidence strongly supports asking about HBOT. The UHMS Clinical Hyperbaric Facility Accreditation Manual (2023) describes what a legitimate wound center looks like.
Traumatic Brain Injury and Neurological Recovery
Brain injury recovery is where HBOT outcomes get the most public attention. The evidence is more mixed than wound healing but the patient stories drive interest.
Military and Veteran TBI
The BIMA trial program (Weaver et al., Lancet Neurology 2018) and follow-up studies have tracked mild TBI in active-duty and veteran populations. Results are mixed across trials, with some showing significant cognitive and PTSD symptom improvement at 1.5 ATA versus sham and others finding sham equivalence.
The Department of Veterans Affairs began offering HBOT for service-connected mild TBI under a pilot in 2017, which expanded to all VA medical centers with hyperbaric capability in 2023.
Mechanism in Chronic Brain Injury
In chronic TBI, there are often areas of metabolically suppressed neurons — "idling" cells that aren't dead but aren't functioning fully due to reduced oxygen delivery.
HBOT appears to address these regions by raising tissue oxygen, reducing neuroinflammation, and stimulating neuroplastic repair pathways per the 2024 Frontiers in Neurology systematic review.
Stroke Recovery
A randomized trial from Tel Aviv University (Efrati et al., PLOS ONE 2013) demonstrated that HBOT initiated months to years after stroke could improve motor function and quality of life. The study used SPECT imaging to confirm increased metabolic activity in previously damaged brain regions.
A more recent 2023 Stroke journal study by Tal et al. found cognitive improvements in chronic post-stroke patients receiving HBOT. See the stroke recovery evidence atlas for the full investigational evidence breakdown.
Honest Limitations
Not every TBI patient responds. The published trials show meaningful improvement in roughly 60-70% of chronic TBI patients in the protocols that demonstrated benefit, meaning 30-40% don't see significant gains.
Factors that predict better outcomes include younger age, shorter time since injury, and absence of severe structural brain damage on MRI per Hadanny et al., Frontiers in Human Neuroscience 2022.
TBI is off-label per the FDA Safety Communication (2021, reaffirmed 2024). Insurance coverage outside the VA pilot is essentially zero.
Long COVID: The Condition That Brought HBOT Mainstream
Long COVID may be the condition most responsible for bringing HBOT into mainstream public conversation in the 2020s.
The Sham-Controlled RCT
The landmark trial from Shamir Medical Center was published in Zilberman-Itskovich et al., Scientific Reports 2022.
- 73 post-COVID patients with persistent cognitive symptoms
- 40 sessions at 2.0 ATA on 100% oxygen, 90 minutes per session, 5 days per week
- HBOT group versus sham group
- Significant improvement in global cognitive function, attention, executive function
- Significant reductions in fatigue, sleep disturbance, psychiatric symptoms, and pain
Durability
The 1-year follow-up published in Hadanny et al., Scientific Reports 2024 confirmed improvements were maintained post-treatment.
Durability matters because it answers the question skeptics raised: does HBOT produce lasting change or temporary relief?
Proposed Mechanism
The proposed mechanism for long COVID involves several pathways per the 2024 Frontiers in Medicine narrative review:
- Reducing neuroinflammation that drives brain fog
- Improving mitochondrial function in virus-damaged cells
- Addressing microclotting that impairs capillary flow per Pretorius et al., Cardiovascular Diabetology 2021
Response Rates and Limitations
Not every long COVID patient responds. Across the Shamir trial cohort, roughly 70-75% of patients showed meaningful improvement.
Patients with primarily cognitive symptoms responded more strongly than those with severe cardiovascular involvement.
Long COVID is off-label per CMS NCD 20.29. Coverage is denied. Cash protocols run $10,000-$24,000 at private clinics.
Carbon Monoxide Poisoning: An Emergent On-Label Win
CO poisoning is one of the strongest on-label HBOT indications. It's also one of the least visible because outcomes are emergent rather than chronic.
The Weaver et al., NEJM 2002 trial established HBOT's role in preventing cognitive sequelae from acute CO poisoning. Patients receiving HBOT within 6-24 hours of exposure had significantly lower rates of cognitive impairment at 6 weeks and 12 months versus normobaric oxygen alone.
CO poisoning treatment is covered automatically at any hospital with a hyperbaric chamber. No prior authorization. The UHMS 15th Edition Indications (2025) details the protocol.
Sudden Sensorineural Hearing Loss
Idiopathic sudden sensorineural hearing loss (ISSHL) is a partial-coverage indication. The American Academy of Otolaryngology Clinical Practice Guideline (2019, reaffirmed 2024) lists HBOT as a treatment option within 14 days of symptom onset. See the sudden sensorineural hearing loss evidence atlas for the full study-by-study evidence breakdown.
Coverage varies: Aetna covers ISSHL, Cigna does not, BCBS varies by state per the comparison in our HBOT Insurance Coverage 2026 guide.
The Cochrane Review by Bennett et al. (2012, updated 2024) found HBOT improved hearing in some ISSHL patients, with strongest effects in moderate-to-severe loss treated early.
What to Expect From Your Own Course
Standard Protocol
Most on-label and off-label protocols follow a similar shape per the UHMS 15th Edition Indications (2025).
- Pressure: 2.0-2.4 ATA depending on indication
- Oxygen: 100% medical grade
- Session length: 90 minutes including pressurization and depressurization
- Frequency: 5 sessions per week (Monday-Friday)
- Total sessions: 20-60 depending on indication
Timeline Expectations
These are population-level patterns, not guarantees.
- Sessions 1-5: First-session acclimatization fades. Ear-clearing becomes automatic.
- Sessions 5-15: Some patients report energy and sleep changes. Wound progression may be visible.
- Sessions 15-30: Cognitive changes often emerge in neurological indications. Wound healing typically meaningful by session 30.
- Sessions 30-40: Maximum clinical benefit. Most off-label trial protocols complete here.
- Post-treatment: For the conditions where durability has been measured (long COVID, anti-aging), benefits have persisted at 1 year per Hadanny et al., Scientific Reports 2024.
When People Don't Respond
It's worth being honest. HBOT is not a universal treatment.
Across published trials, non-response rates range from 25-40% depending on indication and patient population. The strongest predictors of non-response include severe structural tissue damage, very long symptom duration before treatment, and comorbid conditions limiting oxygen delivery.
If you're 20-25 sessions in and seeing no measurable change, talk to your physician about whether continuing is warranted.
Cost and Coverage Reality
| Indication | Coverage | Typical Out-of-Pocket |
|---|---|---|
| Diabetic foot ulcer (Wagner III+) | Medicare/commercial covered | $4,557 (40 sessions, Medicare Part B) |
| Radiation tissue injury | Covered | $4,557 (40 sessions, Medicare Part B) |
| CO poisoning | Covered emergent | $0-$500 (acute setting) |
| Sudden sensorineural hearing loss | Aetna/BCBS partial | $1,500-$4,000 |
| Long COVID | Denied | $10,000-$20,000 |
| Traumatic brain injury | Denied (VA pilot for veterans) | $13,000-$24,000 |
| Anti-aging / longevity | Denied | $18,000-$30,000 |
Full coverage breakdown in our HBOT Insurance Coverage 2026 guide.
Frequently Asked Questions
How quickly should I expect to feel a difference?
It varies by indication. Wound patients see measurable progress assessed by their physician at sessions 10-20. Off-label neurological indications often see cognitive changes around sessions 15-20. CO poisoning treatment is acute and outcomes are measured at 6 weeks per Weaver et al., NEJM 2002. If you're 20+ sessions in with zero change, discuss continuation with your physician.
What percentage of patients respond?
Response rates vary by indication and protocol. For diabetic foot ulcers in the Löndahl et al., Diabetes Care 2010 trial, complete healing was 52% with HBOT versus 29% without. For long COVID in the Shamir RCT (Zilberman-Itskovich et al., 2022), roughly 70-75% showed meaningful improvement. For TBI, the BIMA program (Weaver et al., Lancet Neurology 2018) found roughly 60-70% improvement in responders, with about 30-40% non-response.
Is HBOT safe across 40+ sessions?
Yes, when delivered at UHMS-accredited facilities. The most common side effect is mild middle-ear barotrauma during early sessions, usually resolved with slower pressurization per StatPearls HBOT Complications (2024). Transient near-sightedness over 20-40 sessions typically reverses within 6-8 weeks of completion. Serious adverse events are rare; the FDA Safety Communication (2021) documents the safety record.
What's the difference between a "success story" and clinical evidence?
Anecdotes describe individual experiences. Clinical evidence comes from controlled trials that measure outcomes against placebo or standard care. Both have value but they answer different questions. Anecdotes tell you "this happened to someone." Evidence tells you "this is more likely than chance to happen across a population." For HBOT, the strongest evidence is in wound healing and CO poisoning. The most-discussed anecdotes involve neurological and longevity uses where evidence is earlier-stage.
How do I find a legitimate HBOT center?
Look for UHMS Facility Accreditation, a board-certified hyperbaric physician (UHM subspecialty or ABPM), Certified Hyperbaric Technologist (CHT) operating the chamber, and Class A hard-shell chambers for medical-grade treatment. The UHMS Clinical Hyperbaric Facility Accreditation Manual (2023) details the standards. Avoid wellness clinics offering "mild HBOT" at 1.3 ATA for medical claims; the FDA Safety Communication (2021) warns this is not equivalent to clinical-grade therapy.
Related Reading
- HBOT Insurance Coverage in 2026: 14 Approved Indications Decoded
- HBOT for Long COVID: Current Clinical Evidence
- Hyperbaric Oxygen Therapy for Anti-Aging and Longevity
- Your First HBOT Session: Complete Preparation Guide
- The Complete Beginner's Guide to Hyperbaric Oxygen Therapy
Find HBOT Centers Near You
Browse our directory of UHMS-accredited HBOT centers to find a clinical-grade facility near you.
-- The HBOT Finder Team
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Individual results vary significantly based on condition, severity, and individual response. HBOT should be pursued only under qualified physician supervision at a UHMS-accredited facility.
Editorial Disclosure: HBOT Finder maintains editorial independence. We do not accept paid placements in our clinic directory.